Financial Times analysis raises legitimate questions about Palantir's NHS performance claims, noting that success appears concentrated in a small number of hospitals rather than showing broad impact across the system. However, the specific numbers cited—like the claim that a third of trusts showed declining performance—cannot be verified from available public reporting. The analysis accurately flags that case studies tend to highlight selective metrics. Chelsea and Westminster, for example, reported substantial gains including a 28% reduction in inpatient elective waiting lists and higher theatre utilisation after deploying Palantir's Foundry platform—but these represent success stories rather than typical outcomes across the NHS. The underlying concern about cherry-picked data is sound. The added commentary about Westminster's proximity to political power goes beyond what the reporting establishes and reads more like speculation than verified fact.